Galapagos (GLPG)
(Delayed Data from NSDQ)
$29.58 USD
+0.24 (0.82%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.62 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.58 USD
+0.24 (0.82%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.62 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Zacks News
Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
by Zacks Equity Research
Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan
by Zacks Equity Research
Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.
Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
Galapagos NV (GLPG) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Galapagos NV (GLPG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Gilead & Galapagos Close Research & Development Agreement
by Zacks Equity Research
Gilead (GILD) closes collaboration agreement with Galapagos, per which the latter will receive an upfront license fee payment of $3.95 billion.
Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe
by Zacks Equity Research
The EMA accepts Gilead (GILD) and Galapagos' MAA for filgotinib as a treatment for rheumatoid arthritis.
Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised
by Zacks Equity Research
Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.
Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings?
by Zacks Equity Research
Investors are expected to focus on the HIV franchise's performance and other pipeline updates, when Gilead (GILD) reports second-quarter 2019 results.
Top Ranked Momentum Stocks to Buy for July 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 26th
Galapagos NV (GLPG) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Galapagos NV (GLPG).
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
by Zacks Equity Research
Key highlights of the past week include collaborations and other pipeline updates.
Company News for Jul 16, 2019
by Zacks Equity Research
Companies In The News Are: SYMC,AVGO,GLPG,GILD,BA,AAL,UNIT
Gilead-Galapagos Ink $5.1B Deal for Additional Compounds
by Zacks Equity Research
Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.
Gilead to Submit NDA for Inflammation Drug Filgotinib in '19
by Zacks Equity Research
Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.
Galapagos Ends Enrollment in Osteoarthritis Study Before Time
by Zacks Equity Research
Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.
Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum
by Zacks Equity Research
Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
by Zacks Equity Research
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
Gilead & Galapagos Announce Positive Data on Arthritis Drug
by Zacks Equity Research
Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.
AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
by Zacks Equity Research
AMAG's (AMAG) share improve 9.7% year to date courtesy of label expansion efforts as well as acquisitions and deals.
Galapagos' Osteoarthritis Candidate Gets Fast Track Status
by Zacks Equity Research
Galapagos' (GLPG) GLPG1972/S201086 gets Fast Track designation by the FDA for the treatment of osteoarthritis.
Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
by Zacks Equity Research
CHMP gives positive opinion to Vertex's (VRTX) label expansion of Orkambi.
Why Galapagos (GLPG) Might Surprise This Earnings Season
by Zacks Equity Research
Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Bayer (BAYRY) This Earnings Season?
by Zacks Equity Research
Bayer (BAYRY) is scheduled to report third-quarter earnings on Nov 13. Acquisition of Mosanto is expected to boost sales of Crop Science segment significantly.
Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?
by Zacks Equity Research
Gilead Sciences (GILD) is scheduled to report third-quarter results on Oct 25. We expect investors to focus on the strong HIV franchise and other pipeline updates.